Investigating the role of PDGF as a potential drug therapy in bone formation and fracture healing

Simon Graham University of Leeds, School of Medicine, Leeds General Infirmary Teaching Hospitals NHS Trust, Academic Department of Trauma and Orthopaedics, Clarendon Wing A, Great George Street, Leeds LS1 3EX, UK +44 0 113 392 2621; +44 0 113 392 3290; [email protected]

, MBChB,

Andreas Leonidou University of Leeds, School of Medicine, Leeds General Infirmary Teaching Hospitals NHS Trust, Academic Department of Trauma and Orthopaedics, Clarendon Wing A, Great George Street, Leeds LS1 3EX, UK +44 0 113 392 2621; +44 0 113 392 3290; [email protected]

, MBChB MRCS,

Marie Lester University of Leeds, School of Medicine, Leeds General Infirmary Teaching Hospitals NHS Trust, Academic Department of Trauma and Orthopaedics, Clarendon Wing A, Great George Street, Leeds LS1 3EX, UK +44 0 113 392 2621; +44 0 113 392 3290; [email protected]

, MBChB,

Manolis Heliotis Reader (Chemical Engineering Department), Imperial College London, England, UK

, MSc FDS FRCS,

Athanasios Mantalaris Reader (Chemical Engineering Department), Imperial College London, England, UK

, PhD &

Eleftherios Tsiridis University of Leeds, School of Medicine, Leeds General Infirmary Teaching Hospitals NHS Trust, Academic Department of Trauma and Orthopaedics, Clarendon Wing A, Great George Street, Leeds LS1 3EX, UK +44 0 113 392 2621; +44 0 113 392 3290; [email protected]

, MD MSc PhD FRCS

Abstract

Background: Platelet-derived growth factor (PDGF) has been shown in vivo to increase bone formation and supplement fracture healing, and may have a role as a therapeutic agent in the treatment of bone loss and fracture healing in humans. Objective: A comprehensive review of the recent literature on the effect of PDGF on bone mineral density and fracture healing. Methods: In vitro and in vivo evidence was systematically collected using medical search engines MEDLINE/OVID (1950 to March 2008) and EMBASE (1980 to March 2008) databases. Results/conclusion: Evidence to date suggests that PDGF-BB, and to a lesser extent PDGF-AA, may have potential therapeutic use in the treatment of osteoporosis and bone healing in humans. Additionally, by targeting α-receptors on osteoblasts, a potential anabolic effect on bone metabolism in humans can be anticipated; however, more research needs to be done to assess the role of β-receptors in human bone.

Keywords::

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Investigating the role of PDGF as a potential drug therapy in bone formation and fracture healing

Information for

Open access

Opportunities

Help and information

Investigating the role of PDGF as a potential drug therapy in bone formation and fracture healing

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature